Ubidecarenone 30mg tablets
Tablet
30mg
Oral
Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone.
Active ingredients:
Ubidecarenone
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ubidecarenone
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ubidecarenone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Show details
Therapeutically similar medicines
Show details
Acoramidis 356mg tablets
Tablet
356mg
Same therapeutic group
Mavacamten 10mg capsules
Capsule
10mg
Same therapeutic group
Mavacamten 15mg capsules
Capsule
15mg
Same therapeutic group
Adenosine 6mg/2ml solution for injection ampoules
Injection
6mg/2ml
Same therapeutic group
Mavacamten 2.5mg capsules
Capsule
2.5mg
Same therapeutic group
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Ubidecarenone
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
95 found
Half-life
21.7 h
Mechanism
Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
7.9 h
Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood.…
Half-life
21.7 h
The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.
[A31414]
[A31414]
Protein binding
95%
In the blood, ubidecarenone is split into the various lipoprotein particles including LDL and VLDL.
[L1065]…
[L1065]…
Volume of distribution
20.4 L/kg
Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain.
[L1065]…
[L1065]…
Metabolism
Studies indicate that there is no saturation process during the metabolism of ubidecarenone.…
Elimination
60%
The main elimination route of ubidecarenone is through the bile.…
Clearance
1.18 ml
In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Investigational
Nutraceutical
Small molecule
About this compound
Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail.[A7874] It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation.[A31413] The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand.[L1062] Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug - it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process.[L1063]
Properties:
solid
Avg. mass: 863.34 Da
DrugBank indication
The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies.
[L1064]
It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.
[L1064]
It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.
Also known as(31)
Co Enzyme Q10
Co-enzyme Q 10
Co-Enzyme Q10
Coenzyme Q 10
Coenzyme Q-10
Coenzyme Q10
CoQ10
Ubidecarenone
Dosage forms(52)
(Oral) — 30 MG
Capsule (Oral) — 50 mg / cap
Capsule (Oral) — 150 mg
Capsule (Oral) — 50 mg
Capsule (Oral) — 30 mg
Stick (Cutaneous)
Capsule (Oral) — 100 mg / cap
Solution (Oral)
Molecular properties(18)
Drug interactions(234)
Known interactions with other medications. Always consult a healthcare professional.
Insulin pork
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin pork.
Troglitazone
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Troglitazone.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metformin.
Acetohexamide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Acetohexamide.
Phenformin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Phenformin.
Gliquidone
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gliquidone.
Mitiglinide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Mitiglinide.
Glisoxepide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glisoxepide.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glymidine.
AICA ribonucleotide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with AICA ribonucleotide.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Buformin.
Vildagliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Vildagliptin.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Voglibose.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with NN344.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with AMG-222.
Bisegliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Bisegliptin.
Alogliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Alogliptin.
Gosogliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gosogliptin.
Glibornuride
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glibornuride.
Benfluorex
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Benfluorex.
Empagliflozin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Empagliflozin.
Albiglutide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Albiglutide.
Dulaglutide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dulaglutide.
Lobeglitazone
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Lobeglitazone.
Netoglitazone
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Netoglitazone.
Rivoglitazone
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Rivoglitazone.
Ciglitazone
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Ciglitazone.
Lixisenatide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Lixisenatide.
Insulin beef
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin beef.
Insulin degludec
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin degludec.
Insulin peglispro
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin peglispro.
Insulin tregopil
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin tregopil.
Ipragliflozin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Ipragliflozin.
Dutogliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dutogliptin.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Allicin.
Tofogliflozin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Tofogliflozin.
2,4-thiazolidinedione
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with 2,4-thiazolidinedione.
Teneligliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Teneligliptin.
Omarigliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Omarigliptin.
Carmegliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Carmegliptin.
Gemigliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gemigliptin.
Anagliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Anagliptin.
Evogliptin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Evogliptin.
Sotagliflozin
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sotagliflozin.
Balaglitazone
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Balaglitazone.
Remogliflozin etabonate
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Remogliflozin etabonate.
Carbutamide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Carbutamide.
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Guar gum.
Metahexamide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metahexamide.
Semaglutide
Unknown severity
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Semaglutide.
Showing 50 of 234 interactions
Food & lifestyle interactions
Advice
Take with or without food. Many different products contain ubidecarenone; refer to the product monograph for more specific instructions.
Toxicity & overdose
There have not been reports of adverse events of diet supplementation with ubidecarenone.
[A31417]
The normal side effects reported in humans are related to the gastrointestinal tract.
[A31416]
[A31417]
The normal side effects reported in humans are related to the gastrointestinal tract.
[A31416]
How it works
Mechanism of action
Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain.[A31416] Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol.[L1065]
Pharmacodynamics
Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension.[A31413]
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet.
The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks.
[L1065]
The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.
[A31414]
The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks.
[L1065]
The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.
[A31414]
Half-life
The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.
[A31414]
[A31414]
Protein binding
In the blood, ubidecarenone is split into the various lipoprotein particles including LDL and VLDL.
[L1065]
The plasma concentration of ubidecarenone is highly dependent on the presence of plasma lipoproteins and about 95% of the administered form is found in the reduced form.
[A31416]
[L1065]
The plasma concentration of ubidecarenone is highly dependent on the presence of plasma lipoproteins and about 95% of the administered form is found in the reduced form.
[A31416]
Volume of distribution
Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain.
[L1065]
In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues.
[A31415]
AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.
[A31416]
[L1065]
In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues.
[A31415]
AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.
[A31416]
Metabolism
Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine.
[L1066]
After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.
[A31416]
[L1066]
After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.
[A31416]
Route of elimination
The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites.
[L1065][A31416]
In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.
[A31416]
[L1065][A31416]
In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.
[A31416]
Clearance
In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.
[A31415]
[A31415]
Drug targets(2)
Proteins and enzymes this drug interacts with in the body
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial
NDUFV3
cofactor
Specific functionNADH dehydrogenase (ubiquinone) activity
Cellular location
Mitochondrion inner membrane
General function & pharmacology
Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.
May be the terminally assembled subunit of Complex I
May be the terminally assembled subunit of Complex I
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
SDHA
cofactor
Specific functionelectron transfer activity
Cellular location
Mitochondrion inner membrane
General function & pharmacology
Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) .
PMID:10746566 PMID:24781757
SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate (By similarity). Can act as a tumor suppressor PMID:20484225
PMID:10746566 PMID:24781757
SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate (By similarity). Can act as a tumor suppressor PMID:20484225
Metabolizing enzymes(1)
Enzymes involved in drug metabolism — important for understanding drug interactions
Enzyme activity key
substrate
inhibitor
inducer
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductase
substrate
Transporters(1)
Proteins that transport this drug across cell membranes
ATP-dependent translocase ABCB1
ABCB1
substrate
Specific functionABC-type xenobiotic transporter activity
Cellular location
Cell membrane
General function & pharmacology
Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
Carriers(2)
Proteins that carry this drug through the body
Low-density lipoprotein receptor
LDLR
substrate
Specific functionamyloid-beta binding
Cellular location
Cell membrane
General function & pharmacology
Binds low density lipoprotein /LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Forms a ternary complex with PGRMC1 and TMEM97 receptors which increases LDLR-mediated LDL internalization PMID:30443021
Very low-density lipoprotein receptor
VLDLR
substrate
Specific functionapolipoprotein binding
Cellular location
Cell membrane
General function & pharmacology
Multifunctional cell surface receptor that binds VLDL and transports it into cells by endocytosis and therefore plays an important role in energy metabolism. Also binds to a wide range of other molecules including Reelin/RELN or apolipoprotein E/APOE-containing ligands as well as clusterin/CLU .
PMID:24381170 PMID:30873003
In the off-state of the pathway, forms homooligomers or heterooligomers with LRP8 .
PMID:30873003
Upon binding to ligands, homooligomers are rearranged to higher order receptor clusters that transmit the extracellular RELN signal to intracellular signaling processes by binding to DAB1 .
PMID:30873003
This interaction results in phosphorylation of DAB1 leading to the ultimate cell responses required for the correct positioning of newly generated neurons. Later, mediates a stop signal for migrating neurons, preventing them from entering the marginal zone (By similarity)
PMID:24381170 PMID:30873003
In the off-state of the pathway, forms homooligomers or heterooligomers with LRP8 .
PMID:30873003
Upon binding to ligands, homooligomers are rearranged to higher order receptor clusters that transmit the extracellular RELN signal to intracellular signaling processes by binding to DAB1 .
PMID:30873003
This interaction results in phosphorylation of DAB1 leading to the ultimate cell responses required for the correct positioning of newly generated neurons. Later, mediates a stop signal for migrating neurons, preventing them from entering the marginal zone (By similarity)
Scientific references(6)
Ernster L., Dallner G.
Biochemical, physiological and medical aspects of ubiquinone function.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
19951271(1):195-204. doi: 10.1016/0925-4439(95)00028-3
Xue R., Yang J., Wu J., Meng Q., Hao J.
Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway.
Oncotarget
2017 Sep 238(54):92300-92311. doi: 10.18632/oncotarget.21247. eCollection 2017 Nov 3
Kang E.Y., Choi J.W., Gwak H.S., Chun I.K.
Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers.
International
Journal of Clinical Pharmacology and Therapeutics. 200947(03):207-214. doi: 10.5414/cpp47207
Kalenikova E.I., Gorodetskaya E.A., Medvedev O.S.
Pharmacokinetics of coenzyme Q10.
Bulletin of Experimental Biology and Medicine
2008146(3):313-316. doi: 10.1007/s10517-008-0270-8
Bhagavan H.N., Chopra R.K.
Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics.
Free Radic Research
2006 May40(5):445-53. doi: 10.1080/10715760600617843
Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M.
The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic—Reply.
Archives of Neurology
200360(8):1172. doi: 10.1001/archneur.60.8.1172
ATC classification(1 code)
ATC C01EB09
Affected organisms(1)
Humans and other mammals
Salt forms(1)
Coenzyme q10, (2z)-(DBSALT001598)
Experimental properties(3)
Protein Data Bank entries(202)
1aig
1aij
1bcc
1ds8
1dv3
1dv6
1e14
1e6d
1f6n
1fnp
1fnq
1jgw
1jgx
1jgy
1jgz
1jh0
1k6l
1k6n
1kby
1l9b
1l9j
1m3x
1mps
1ogv
1pcr
1pss
1pst
1qov
1rg5
1rgn
1rqk
1rvj
1ry5
1rzh
1rzz
1s00
1umx
1yf6
1yst
1z9j
1z9k
2bcc
2bnp
2bns
2boz
2gmr
2gnu
2hg3
2hg9
2hh1
2hhk
2hit
2hj6
2j8c
2j8d
2jiy
2jj0
2uws
2uwt
2uwu
2uwv
2uww
2ux3
2ux4
2ux5
2uxj
2uxk
2uxl
2uxm
2wx5
3dsy
3dta
3dtr
3dts
3du2
3du3
3duq
3i4d
3kp9
3v3y
3v3z
3zum
3zuw
4h99
4h9l
4hbh
4hbj
4in5
4in6
4in7
4lwy
4n7k
4n7l
4nv2
4nv5
4nv6
4rcr
4tqq
4u3f
4v9g
5lri
5lse
5v33
6q9e
6z02
6z1j
6z27
6z5r
6z5s
7a23
7ddq
7eqd
7f0l
7mh3
7mh4
7mh5
7mh8
7mh9
7mha
7od5
7oy8
7p0q
7p17
7p2c
7pil
7pqd
7qsk
7qso
7rja
7rjb
7rjc
7rjd
7tgh
7va9
7vb9
7vnm
7vny
7vor
7vot
7voy
7vy2
7vy3
7xxf
7yml
7z8d
8asi
8asj
8b64
8c3f
8c5x
8c6k
8c7c
8c87
8c88
8e73
8esz
8gy2
8gy3
8gym
8gzu
8iao
8iar
8ib4
8ib7
8ib9
8ibc
8ibd
8ibg
8ic2
8ic5
8iuf
8j9h
8j9i
8j9j
8jej
8jek
8k6j
8k6k
8q0m
8q1b
8q1u
8q25
8q45
8q47
8q48
8q4a
8qby
8smr
8snh
8uep
8ueq
8uer
8uez
8ugd
8uge
8ugf
8ugg
8vtj
8vtk
8vto
8xcm
8xcn
Commercial products(154)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ubidecarenone
Additional database identifiers
Drugs Product Database (DPD)
1357
ChemSpider
4445197
PDB
U10
ZINC
ZINC000085427689
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7719
GenAtlas
NDUFV3
GeneCards
NDUFV3
GenBank Gene Database
X99726
GenBank Protein Database
6002197
UniProt Accession
NDUV3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10680
GenAtlas
SDHA
GeneCards
SDHA
GenBank Gene Database
D30648
GenBank Protein Database
506338
UniProt Accession
SDHA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5006
GenAtlas
HMGCR
GeneCards
HMGCR
GenBank Gene Database
M11058
GenBank Protein Database
306865
Guide to Pharmacology
639
UniProt Accession
HMDH_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6547
GenAtlas
LDLR
GeneCards
LDLR
GenBank Gene Database
L00352
GenBank Protein Database
307121
UniProt Accession
LDLR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12698
GeneCards
VLDLR
GenBank Gene Database
L20470
GenBank Protein Database
409426
UniProt Accession
VLDLR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 27 days ago(8 Mar 2026)